X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pembrolizumab (2772) 2772
oncology (1517) 1517
nivolumab (1364) 1364
immunotherapy (1301) 1301
index medicus (1293) 1293
humans (901) 901
ipilimumab (828) 828
cancer (808) 808
melanoma (774) 774
chemotherapy (768) 768
open-label (581) 581
metastasis (500) 500
patients (469) 469
docetaxel (432) 432
tumors (429) 429
lung cancer (418) 418
care and treatment (399) 399
female (395) 395
male (391) 391
pd-1 (391) 391
pd-l1 (371) 371
immunology (370) 370
survival (362) 362
middle aged (357) 357
safety (351) 351
immune checkpoint (337) 337
multicenter (328) 328
aged (327) 327
apoptosis (322) 322
cancer therapies (320) 320
clinical trials (320) 320
therapy (306) 306
blockade (275) 275
metastases (274) 274
cell lung-cancer (273) 273
pd-1 protein (263) 263
programmed cell death 1 receptor - antagonists & inhibitors (259) 259
metastatic melanoma (255) 255
respiratory system (247) 247
expression (240) 240
research (237) 237
pd-l1 protein (234) 234
atezolizumab (222) 222
analysis (221) 221
lymphocytes (221) 221
adult (220) 220
antibodies, monoclonal - therapeutic use (218) 218
pd-1 blockade (214) 214
lung cancer, non-small cell (206) 206
advanced melanoma (204) 204
antineoplastic agents - therapeutic use (204) 204
immunotherapy - methods (201) 201
biomarkers (193) 193
antibodies, monoclonal, humanized - therapeutic use (189) 189
mutation (189) 189
treatment outcome (189) 189
drug therapy (188) 188
melanoma - drug therapy (188) 188
cell death (187) 187
medical research (185) 185
immune checkpoint inhibitors (183) 183
ligands (183) 183
checkpoint inhibitors (178) 178
prognosis (173) 173
immunohistochemistry (172) 172
anti-pd-1 (167) 167
medicine, research & experimental (166) 166
aged, 80 and over (163) 163
medicine & public health (161) 161
non-small cell lung cancer (161) 161
antibodies (154) 154
carcinoma (152) 152
adverse events (150) 150
medical prognosis (150) 150
health aspects (148) 148
antineoplastic agents, immunological - therapeutic use (145) 145
lung neoplasms - drug therapy (145) 145
trial (143) 143
programmed cell death 1 receptor - immunology (142) 142
t-cells (141) 141
toxicity (141) 141
review (139) 139
nsclc (137) 137
pharmacology & pharmacy (137) 137
lymphocytes t (134) 134
antibodies, monoclonal, humanized - adverse effects (133) 133
usage (133) 133
antibody (131) 131
antibodies, monoclonal - adverse effects (130) 130
cytotoxicity (130) 130
inhibitors (130) 130
carcinoma, non-small-cell lung - drug therapy (124) 124
untreated melanoma (124) 124
case report (121) 121
development and progression (120) 120
b7-h1 antigen - antagonists & inhibitors (118) 118
solid tumors (116) 116
hematology (115) 115
neoplasms. tumors. oncology. including cancer and carcinogens (114) 114
antigens (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2706) 2706
French (39) 39
German (39) 39
Korean (10) 10
Russian (7) 7
Spanish (7) 7
Japanese (3) 3
Czech (2) 2
Icelandic (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Der Urologe. Ausg. A, ISSN 0340-2592, 01/2019, Volume 58, Issue 1, pp. 45 - 48
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2019, Volume 37, Issue 11, pp. 940 - 940
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 17, pp. 1658 - 1667
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II... 
ONCOLOGY | NIVOLUMAB | PEMBROLIZUMAB | Rapid Communications
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 03/2016, Volume 14, Issue 3, pp. 255 - 264
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines... 
PEMBROLIZUMAB | ONCOLOGY | NIVOLUMAB | IMMUNOTHERAPY | SAFETY | DOCETAXEL
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 178 - 181
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2019, Volume 113, pp. 69 - 71
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 6/2019, Volume 25, Issue 7, pp. 1008 - 1009
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 02/2019, Volume 16, Issue 2, pp. 66 - 66
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 383 - 390
Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with... 
METASTATIC MELANOMA | PEMBROLIZUMAB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | COMBINATION | IPILIMUMAB
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 2018, Volume 58, Issue 6, pp. 739 - 741
Journal Article
Clinical and Experimental Dermatology, ISSN 0307-6938, 07/2019, Volume 44, Issue 5, pp. 570 - 573
Click here for the corresponding questions to this CME article. 
DERMATOLOGY | Radiation | Pembrolizumab
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 14, pp. 1387 - 1388
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 11/2018, Volume 16, Issue 11, pp. 1376 - 1378
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4, pp. 391 - 398
Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with... 
UNTREATED MELANOMA | DABRAFENIB | PEMBROLIZUMAB | MONOTHERAPY | ONCOLOGY | TRAMETINIB | Original Reports
Journal Article
Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1307 - 1316
Background: BRAF(V600E) mutation occurs in 1-2% of lung adenocarcinomas and acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has... 
SURVIVAL | HARBORING BRAF MUTATIONS | 1ST-LINE TREATMENT | MULTICENTER | MELANOMA | PEMBROLIZUMAB | ONCOLOGY | CRIZOTINIB | MULTICOHORT | CHEMOTHERAPY | EGFR
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 11/2018, Volume 41, Issue 11, pp. 1083 - 1088
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.